Maynard Um
-
-
-
-
-
-
-
Coya Therapeutics CEO outlines 2026 priorities in stockholder letter
-
-
-
-
-
-
-
Coya Therapeutics, Inc. (COYA) Tops Q3 EPS by 46c
-
-
-
-
-
-
-
COYA Therapeutics ALS trial accepted by NEALS research consortium
-
-
-
-
-
-
-
H.C. Wainwright Reiterates Buy Rating on Coya Therapeutics (COYA)
-
-
-
-
-
-
-
Atea Pharmaceuticals (AVIR) Appoints Howard H. Berman to Board of Directors and Announces Share Repurchase Program
-
-
-
-
-
-
-
D. Boral Capital Starts Coya Therapeutics (COYA) at Buy, PT $15
-
-
-
-
-
-
-
Coya Therapeutics (COYA) Appoints Arun Swaminathan as Next CEO
-
396,379 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

